Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2356 to 2370 of 7712 results

  1. Pneumonia QS update

    In development [GID-QS10190] Expected publication date: 14 August 2025

    Quality standard
    In development

  2. Artificial intelligence technologies to aid the opportunistic detection of vertebral fragility fractures on radiographic images

    In development [GID-HTE10059] Expected publication date: 20 August 2025

    Health technology evaluations
    In development

  3. Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years TS ID 12092

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma TS ID 12117

    Awaiting development [GID-TA11653] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy TS ID 12115

    Awaiting development [GID-TA11655] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years TS ID 12116

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy ID6509

    Awaiting development [GID-TA11658] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. 12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years ID6510

    Awaiting development [GID-TA11635] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases ID6512

    Awaiting development [GID-TA11657] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513

    Awaiting development [GID-TA11660] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction ID6514

    Awaiting development [GID-TA11651] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 ID6385

    Awaiting development [GID-TA11457] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Transbronchial lung cryobiopsy

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  14. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

    Awaiting development [GID-TA11626] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Deucravacitinib for treating active psoriatic arthritis TS ID 11981

    Awaiting development [GID-TA11510] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development